Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;288(1):23-37.
doi: 10.1111/joim.13042. Epub 2020 Mar 18.

Top 10 candidate aortic disease trials

R L Dalman  1 , A Wanhainen  2 , K Mani  2 , B Modarai  3
Affiliations
Free article
Review

Top 10 candidate aortic disease trials

R L Dalman et al. J Intern Med. 2020 Jul.
Free article

Abstract

Aortic pathologies such as aneurysm, dissection and trauma are relatively common and potentially fatal diseases. Over the past two decades, we have experienced unprecedented technical and medical developments in the field. Despite this, there is a great need, and great opportunities, to further explore the area. In this review, we have identified important areas that need to be further studied and selected priority aortic disease trials. There is a pressing need to update the AAA natural history and the role for endovascular AAA repair as well as to define biomarkers and genetic risk factors as well as influence of gender for development and progression of aortic disease. A key limitation of contemporary treatment strategies of AAA is the lack of therapy directed at small AAA, to prevent AAA expansion and need for surgical repair, as well as to reduce the risk for aortic rupture. Currently, the most promising potential drug candidate to slow AAA growth is metformin, and RCTs to verify or reject this hypothesis are warranted. In addition, the role of endovascular treatment for ascending pathologies and for uncomplicated type B aortic dissection needs to be clarified.

Keywords: aneurysm; aorta; clinical trials; dissection; endovascular; medical treatment; surgery.

PubMed Disclaimer

References

    1. Stather PW, Sidloff DA, Rhema IA, Choke E, Bown MJ, Sayers RD. A review of current reporting of abdominal aortic aneurysm mortality and prevalence in the literature. Eur J Vasc Endovasc Surg 2014; 47: 240-2.
    1. Schermerhorn ML, Bensley RP, Giles KA et al. Changes in abdominal aortic aneurysm rupture and short-term mortality, 1995-2008: a retrospective observational study. Ann Surg 2012; 256: 651-8.
    1. Nelissen BG, Herwaarden JA, Pasterkamp G, Moll FL, Vaartjes I. Shifting abdominal aortic aneurysm mortality trends in The Netherlands. J Vasc Surg 2015; 61: 642-47.e2.
    1. Wolford BN, Hornsby WE, Guo D et al. Clinical implications of identifying pathogenic variants in individuals with thoracic aortic dissection. Circ Genom Precis Med 2019;12:e002476.
    1. Li J, Pan C, Zhang S et al. Decoding the genomics of abdominal aortic aneurysm. Cell 2018; 174: 1361-72.e10.

LinkOut - more resources